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Original Article
Abstract
Purpose: The aim of this study is to report the treatment outcomes, toxicities, and dosimetric feasibility of simultaneous inte-
grated boost by RapidArc (RA-SIB) compared with 3dimentional-conformal radiation therapy (3D-CRT) for patients with glio-
blastoma. Methods: Eleven patients with unifocal glioblastoma (grade IV astrocytoma, WHO classification) were treated during
the period from April 2011 until February 2013 with postoperative irradiation and concomitant temozolomide 75 mg/m2 fol-
lowed by 6-12 months of adjuvant temozolomide 200 mg/m2 for 5 days/4weeks. One patient received temozolomide for 12
months, 5patients for 6 months, and 5patients did not receive adjuvant temozolomide. RA-SIB technique was used and patients
received 46 Gy per fraction of 2 Gy in 23 sessions on the planning target volume (PTV1) (contrast enhancement + per-focal edema
as seen in T2 MR + 2.3 cm) with concomitant daily superimposed boost (SIB) on PTV2 corresponding to the contrast enhance-
ment + 2.3 cm. The treatment outcomes and toxicity were assessed. Dose Volume Histogram DVH analysis was performed be-
tween SIB-RA and 3D-CRT plans of each patient. For the PTV, the comparison parameters included, the mean dose, the standard
deviation, maximum dose, conformity index (CI), and homogeneity index (HI). Results: The median progression free survival
(PFS) and overall survival (OS) were 13 months (95% CI, 8.2-17.8), and 16 months (95% CI, 2.1-29.9) respectively. Four of six
patients (67%) showed local progression (recurrence) after initial response, all recurrences occurred at the site of PTV2. Seven
patients experienced acute grade 1-2 toxicities during the treatment. Late post radiation brain edema was reported in 3 patients.
Conclusion: The SIB-RA did not prove the superiority in survival outcomes compared with the historical data using 3D-CRT.
From the dosimetric standpoint, SIB-RA is a superior technique with respect to 3D-CRT when there are overlaps between organs
at risk (OARs) and PTV.
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Introduction
Glioblastomas are rapidly growing primary brain tumors
associated with a high degree of morbidity and mortality.
Current management is based on maximal cytoreduction with
surgery followed by combined chemo-radiotherapy. Despite
this multi-disciplinary approach to treatment, glioblastoma
remains a life-threatening disease with median survival be-
tween 11 to 18 months.1, 2 The current standard of care in
newly diagnosed GBM patients consists of concomitant low
dose temozolomide with radiation, followed by high dose
adjuvant temozolomide for 6 to 12 months. Despite repre-
senting progress, this approach still does not offer cure to
these patients, as long-term prognosis remains poor, sug-
gesting that alternative therapeutic strategies are desperately
needed.1 Intensity modulated radiation therapy (IMRT)
technique allows the planning and irradiation of different
targets at different dose levels in a single treatment session,
instead of successive treatment plans. These IMRT dose gra-
dients are introduced in such a manner that normal tissues
receive a much lower dose per fraction. Based on the line-
ar-quadratic (LQ), for a similar total physical (nominal) dose,
lowering the dose per fraction to below 2 Gy will reduce the
biological effect, while increasing the dose per fraction to
above 2 Gy will increase that effect.3 The term "simultaneous
integrated boost" (SIB) defines such treatment, delivering
different doses per fraction in different target regions.4 The
SIB technique offers the biological advantage of shortened
treatment duration, i.e. 70 Gy over 6 weeks, which has been
shown to significantly increase the loco-regional control
compared to the same dose delivered in 7 weeks.5 Assuming a
37 value of 2, such an increase in the biological dose of 7.5%
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could be translated into an increase in loco-regional control
in the order of 15%.6
Irradiation with intensity-modulated dose application led to
an improvement in target coverage compared with 3D-CRT
in different tumor entities, like head and neck 7, lung 8, breast
9 or prostate 10, 11. For radiotherapy of Glioblastomas the fea-
sibility and efficacy of IMRT planning with a simultaneous
boost was shown by Chan et al. 12However, Narayana et al.
found no improvement in target coverage using IMRT in
high-grade gliomas in comparison with 3D-CRT. Neverthe-
less, the normal brain, which received a dose of ≥ 18 and ≥ 24
Gy as well as the mean dose to the brainstem, could be re-
duced with IMRT.13 In contrast, MacDonald demonstrated in
similar analysis improved target coverage and also confirmed
reduced radiation dose to the brain, brainstem and optic
chiasm.14 Goswami et al. 15demonstrated that the number of
monitor units was 1.5 times lower for RapidArc and 2 times
higher than 3D conformal technique.
We found that the irradiation time of RapidArc fields was 3
times faster than that of IMRT and 1.5 times faster than that
of 3D conformal technique. RapidArc was even about 5 times
faster than IMRT because of additional time that is necessary
to move the gantry between different IMRT fields. The aim of
this study is to report the treatment outcomes, toxicities, and
dosimetric feasibility of simultaneous integrated boost by
Rapid Arc (RA-SIB) compared with 3-DCRT.
Methods and Materials
Local institutional research ethics board approval was ob-
tained to select eleven patients after diagnosis as Glioblasto-
ma Multiform (WHO grade IV) during the period from April
2011 until February 2013.
Patients’ criteria and tumor locations are listed in Tables 1
and 2. All Patients had unifocal glioblastoma (grade IV as-
trocytoma, WHO classification), Aged ≥ 18 years with resec-
table GBM and the patient has received curative surgery, or
unresectable and the diagnosis was confirmed by a biopsy of
tumor tissue. Surgery or biopsy had occurred ≤ 45 days before
the start of radiotherapy, Zubrod performance status ≤ 2.
Hematologic, renal, and hepatic status were documented
before entry into the study and negative serum pregnancy
test performed before starting treatment for females in child
bearing potential.
CT Simulation
Patients were immobilized supine using an individualized
thermoplastic mask. Planning CT and magnetic resonance
imaging scans, both with a 3 mm slice thickness, were fused
to aid tumor delineation.
TABLE 1: Patient characteristics.
Characteristic No. of
patients
% of total
no. of patients
Age (years)
Mean 56 (28-72)
Gender
Male 7 64
Female 4 46
Duration of symptoms (months)
˂4 5 45.4
≥4 6 54.6
Presenting symptoms/sings
Headache 6 54.6
Convulsions 5 45.4
Hemiplegia/Hemiparesis 4 36.3
Amnesia 1 9.1
Dysartheria 1 9.1
Zubrod PS
0 2 18.2
1 5 45.4
2 4 36.4
Initial tumor size
˂5 3 27.4
≥5 8 72.6
Initial Tumor location
Frontal 1 9.1
Fronto-parital 4 36.3
Temporal 2 18.2
Tempro-parital 2 18.2
Tempro-frontal 2 18.2
Laterality
Right sided 8 72.6
Left sided 3 27.4
Extent of surgery
Biopsy 5 45.4
Subtotal excision 4 36.3
Near total excision 2 18.2
Adjuvant temozolomide
Yes 6 54.6
No 5 45.4
TABLE 2: Tumor location and PTVs.
Location PTV1 (Cm3) PTV2 (Cm3)
Rt. Fronto-parital 301.1 211.0
Rt. Temporal 428.5 244.6
Rt. Tempro-parital 352.2 242.6
Rt. Fronto-tempro-parital 542.6 187.3
Lt. Frontal 357.5 182.6
Rt. Temporal 643.3 337.6
Lt. Fronto-parital 209.6 95.7
Rt. Fronto-temporal 650.3 343.3
Rt. Tempro-parital 465.5 279.7
Rt. Fronto-parital 247.2 157.1
Rt. Fronto-parital 330.7 211.4
Treatment planning and Target volume definition
Target volumes were based upon postoperative-enhanced
MRI. Preoperative imaging was used for correlation and
improved identification. Two planning target volumes (PTV)
were defined, the initial gross tumor volume (GTV1) was
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defined by either the T2 or the FLAIR abnormality (perifocal
edema) on the post-operative MRI scan, MRI enhancements,
and the surgical cavity. The initial clinical target volume
(CTV1) was the (GTV1) plus a margin of 2 cm. The boost
gross tumor volume (GTV2) was defined by the con-
trast-enhanced T1 abnormality on the post-operative MRI
scan and the surgical cavity margins. The boost clinical target
volume (CTV2) was the GTV2 plus a margin of 2.0 cm. The
CTV margin was reduced to 0.5 cm around natural barriers
such as the skull, ventricles, and falx, and also to allow sparing
of the optic nerve/chiasm, if necessary. The planning target
volume (PTV) is an additional margin of 3 mm. Reducing
PTV margins to modify organ at risk (OAR) dose(s) was not
generally permissible. However, OAR was defined, along
with a planning risk volume (PRV) for each OAR. Each PRV
was its OAR plus 3 mm. In the event that an OAR was in
immediate proximity to a PTV such that dose to the OAR
cannot be constrained within protocol limits, a second PTV
(PTV overlap), defined as the overlap between the PTV and
the particular PRV of concern, was created and dose to PRV
did not exceed OAR dose limits.
Treatment planning and dose constrain
The plans for RA and 3D were performed by two different
planners each had excellent experience in treatment plan-
ning. All plans were reviewed by the supervising physicist.
All 3D and RA plans were generated using 6-MV photon
beams commissioned for a Varian CL21EX linear accelerator
and Millennium 120-leaf Multileaf collimator (MLC) (5-mm
width leaves over target extent). A dose calculation grid of 2.5
mm was used for both plans. Final dose calculation was per-
formed using the anisotropic analytical algorithm (AAA),
including heterogeneity management. The DVH calculations
were also performed in Eclipse.
The 3D-CRT planning was performed by forward planning
designed based on the standard RTOG regimen 16 for treat-
ment of GBM giving a total dose of 60 Gy in two phases: phase
one plane to the PTV1 aiming at 46 Gy/23 fractions given
over a period of 31 days (5 fractions/week), followed by phase
2 plan aiming at 14 Gy/7 fractions to PTV2 over a period of 9
days (5 fractions/week). Multiple fields either coplanar or
non-coplanar, automatic wedges were used and field shaping
was done through MLCs. The RA-SIB plans were generated
using an in-house inverse planning approach, in which
MLC-shaped fields were progressively added throughout a
single 360° arc during optimization applying Otto’s VMAT
technique in which direct optimization of leaf positions and
the weights of field samples were done simultaneously along
the arc, so eliminating the leaf sequencing step.17 Patients
received 46 Gy per fraction of 2 Gy in 23 sessions on the
PTV1 (contrast enhancement + per-focal edema as seen in T2
MR + 2.3 cm) with concomitant daily superimposed boost
(SIB) on PTV2 corresponding to the contrast enhancement +
2.3 cm. In order to calculate the RTOG equivalent dose
scheme we used the linear quadratic model with ∞/β of 10
giving PTV2 daily fraction of 2.5 for a total dose of 57.5 Gy.
The PTV2 received a daily dose of 2.5 Gy for a cumulative
dose of 57.5 Gy over a period of 31days. The planning goal
was as follows: the 95% of prescription dose encompassed at
least 95% of the PTVs; no more than 20% of the PTVs re-
ceived more than 110% of prescribed dose; no more than 5%
of the target received less than 95% of the prescribed dose;
and no more than 2% of the tissue outside the PTV received
more than 110% of the prescribed dose. For OARs, the tol-
erance dose was as follows: 54 Gy to the brain stem and 60 Gy
point dose as second criteria, 54 Gy to optic nerve, 54 Gy to
optic chiasm, 45 Gy to the spinal cord, 35 Gy mean dose to the
eye, and 6 Gy to the lens.
Chemotherapy
During Radiation therapy temozolomide 75 mg/m2/day was
given daily by oral route followed by 6-12 cycles of te-
mozolomide 200 mg/m2 for 5 days/4week.
Dose volume histogram analysis
Quantitative evaluation of plans was performed by means of
standard dose-volume histogram (DVH) and dosimetric pa-
rameters were calculated and compared for the PTV and
OARs. For the PTV, the comparison parameters included, the
mean dose, the standard deviation, maximum dose, conform-
ity index (CI), and homogeneity index. The CI of the PTV was
defined as:
95%
PTV
VCI= V
where, V95% was volume within the 95% isodose and VPTV was
volume of the PTV. Consequently, CI will be larger than one,
and will increase with decreasing plan conformity. The ho-
mogeneity index (HI) of the PTV described the uniformity of
the dose within the planning target volume was defined as
the ratio of maximum point dose in the PTV divided by the
covering isodose (95%):
PTV Max Dose in %HI = 95
The lower values of HI represented a more homogenous PTV
dose distribution.
Endpoint and follow-up
The primary endpoint in this study was assessment of dosi-
metric potentials and treatment capabilities of SIB-RA versus
3D-CRT. Secondary endpoints included the treatment tox-
icity, failure patterns (local or distant), Progression-free sur-
vival (PFS), and overall survival (OS) times. All the patients
were evaluated at least once per week during radiotherapy.
The patients were followed every 1–2 months for the first 6
months, and every 3 months thereafter. MRI with contrast
enhancement was usually evaluated every 3 months. Radia-
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tion therapy oncology group (RTOG) neurotoxicity scores
were used to evaluate acute and late toxicities.
SPSS software Package version 21.0 was used for statistical
analysis. Events for the calculation of survival were defined as
death from any cause for overall survival (OS) and as disease
progression or death from any cause for progression-free
survival (PFS). These survival rates were calculated from the
date of the start of treatment to the date of the documented
event by using the Kaplan-Meier method. Variables were
described using mean, median, minimum and maximum
values. The Wilcoxon’s matched-pair signed-rank test for
non-parametrically distributed data was used to compare the
means between 3D-CRT and RA-SIB. Values will be ex-
pressed as mean ±standard deviation or as mean value and
the range of the values according to data distribution. All
p-values reported are two-sided and p < 0.05 is considered
significant.
Results
Treatment outcome
With a median follow up period of 13 months (rang, 4-37
months), the median progression free survival (PFS) and
overall survival (OS) were 13 months (95% CI, 8.2-17.8), and
16 months (95% CI, 2.1-29.9), respectively (Figures 1 and 2).
At time of analysis only three patients were still alive, one of
them showed evidence of progression and the other two
patients were free of progression (Table 3). Four of six pa-
tients (67%) showed local progression (recurrence) after
initial response, all recurrences occurred at the site PTV2
(57.5 Gy dose volume).
Toxicity
Radiation treatment was interrupted for 2 weeks in one pa-
tient after 8 fractions due to loss of consciousness and devel-
opment of uncontrolled seizures. Patient was hospitalized and
kept on corticosteroid, intravenous anti-epileptics and oxy-
gen till his condition stabilized. A causal relationship be-
tween this adverse event and the radiotherapy was unclear.
The other ten patients completed the scheduled radiotherapy
without interruption. Seven patients experienced acute grade
2-3 toxicities during the treatment, including grade 2-3
headache in 4 patients, headache and vomiting (grade 2) in 3
patients and seizures in one patient. All acute toxicities were
controllable with corticosteroids, anti-emetics and an-
ti-epileptic drugs; all patients were given prophylactic an-
ti-epileptic drugs after surgery. Late post radiation brain
edema was reported in 3 patients and was associated with
worsening of the neurological symptoms. In one patient it
was associated with increase in the enhancement area on
follow up MRI with no response to medical treatment indi-
cating tumor recurrence. Radiation-induced necrosis was
observed in one patient 10 months post radiation and diag-
nosed during follow up MRI. None of the patients who pro-
gressed after radiation had second surgical intervention.
TABLE 3: Dosimetric comparison between RA –SIB plan and
3D-CRT.
Variables RA-SIB 3D-CRT
P-valueMean (range) Mean (range)
Mean dose to
PTV1/Gy
47.7 (45.7-49.9) 46.9
(46.1-47.7)
0.04
SD of PTV1/ Gy 2.2 (1.3-3.9) 1.4 (0.9-1.8) 0.02
V≤95% PTV1 / % 2.5 (0.1-5.5) 2.1 (0.3-4.2) 0.63
V≥107% PTV1 / % 10.1 (0.0-17.3) 3.1 (0.0-8.5) 0.01
Mean dose to
PTV2/Gy
57.6 (56.3-58.6) 61.2
(60.1-62.2)
0.003
SD of PTV2 1.4 (0.7-2.3) 1.7 (1.1-2.1) 0.05
V≤95% PTV2 / % 2.6 (0.0-4.5) 2.2 (0.0-5.6) 0.6
V≥107% PTV2 / % 0.1 (0.0-4) 1.9 (0.0-7.3) 0.01
FIG. 1: Progression free survival for all patients.
FIG. 2: Overall survival for all patients.
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FIG. 3: Color wash distribution for isodose 54 Gy level. On the left, 3D-CRT plan part of the brainstem and healthy brain tissue were included in
the dose region. On the right side, SIB-RA plan, the PTV is covered nicely with the dose level while sparing the brainstem and healthy brain
tissue.
DVH analysis
Isodose distribution of RA-SIB and 3D-CRT plans of one
patient is illustrated in Figure 3. The sizes of PTV1 and PTV2
were illustrated in Table 2. Both plans achieved 95% isodose
coverage to at least 95% of the PTVs. The dose coverage,
Conformality and homogeneity were equivalent in both
RA-SIB and 3D-CRT (Table 3 and 4). Both the mean dose and
volume of PTV1 receiving dose ≥ 107% is significantly higher
in the RA plan than 3D plan due to the overlapped dose re-
gion between both PTV1 and PTV2 in RA-SIB. On the other
hand, the dose ≥ 107% for PTV2 is significantly higher in 3D
plan than RA plan due to the effect of plan sum. Comparing
the maximum dose to the ipsilateral optic nerve and eye,
there was statistically significant lower doses to these neuro-
logical structures in the RA plan compared with 3D plan by
8.5 Gy (23.5%) and 11.5 Gy (35.2%) respectively (Table 5).
The maximum dose to the brainstem in the 3D plan exceeded
60 Gy in one 3D plan (second criteria for BS tolerance), also,
the mean dose to BS was significantly higher in 3D plan than
in RA plan by 10Gy (43%). The mean dose to the whole brain
was significantly higher in RA plan than 3D-CRT plan by
11.2 Gy (43.5%) as we did not consider the brain as risk organ
in our plan optimization.
TABLE 4: Homogeneity and conformity indices for PTV1 & 2 in RA-SIB and 3D-CRT.
Homogeneity index Conformity index
RA-SIB 3D-CRT P-value RA-SIB 3D-CRT P-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
PTV1 0.83 ± 0.04 0.87 ± 0.2 0.01 1.03 ± 0.04 1.01 ± 0.01 0.41
PTV2 0.89 ± 0.01 0.87 ± 0.02 0.01 1.02 ± 0.1 1.02 ± 0.2 0.67
TABLE 5: Dosimetric comparison between RA-SIB and 3D-CRT for organs at risk.
Variable Dose RA-SIB (Gy) 3D-CRT (Gy)
P-valueMean        (range) Mean         (range)
Normal Brain Maximum 60.7 (55.8-62.5) 60.5       (49.7-66.8) 0.78
Mean 25.8       (1.1-40.2) 14.6        (2.8-37.5) 0.03
Optic chaisma Maximum 36.6       (3.6-51.6) 37.9 (2.7-54.6) 0.28
Mean 30.1 (1.1-45.8) 31.1        (2.1-48.8) 0.47
Ipsilateral Optic nerve Maximum 27.8 (3.0-47.8) 36.3        (2.2-54.1) 0.01
Mean 14.51      (2.6-27.6) 18.68      (0.5-38.9) 0.11
Ipsilateral eye Maximum 21.4 (8.5-40.1) 33          (12.1-51.9) 0.03
Mean 8.7          (2.1-16.1) 7.7         (2.0-17.9) 0.5
Brainstem Maximum 46.1        (6.1-56.1) 50.5         (6.8-60.9) 0.6
Mean 14.4        (2.2-36.9) 24.5         (2.7-39.1) 0.05
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Discussion
In our study dosimetric comparison between SIB-RA and
3D-CRT plans, showed that sparing of the eye, optic tract and
brain steam was better in the SIB-CRT plan. However, the
coverage of both PTVs was equivalent in both plans. The
randomized phase III EORTC/NCIC trial for GBM quality
assurance demonstrated that achieving adequate target cov-
erage while sparing OARs is a real concern in GBM irradia-
tion.18 In this analysis, more than 50% of patients had tumors
in close proximity of optical pathways and/or brainstem. In
19% of the cases field size was reduced to decrease the dose to
adjacent critical structures and 39% of the participating cen-
ters registered PTV under-dosage. From this point of view,
the use of more advanced techniques such as IMRT and
VMAT could be beneficial. According to previous reports 14, 15
IMRT contributes to a moderate decrease in the dose deliv-
ered to critical structures in the brain compared to 3D-CRT
while maintaining target coverage without significant varia-
tions. Chen et al. 19 reported that IMRT seemed to allow
better sparing of organs at risk than 3D-CRT did (P = 0.055).
However, there was no significant difference for toxicities of
irradiation between the IMRT group and the 3D-CRT group.
Also, Chan et al. 13 demonstrated that SIB-IMRT could deliver
a higher dose to the GTV compared to 3D-CRT without ele-
vating the dose delivered to organs at risk. At the same time,
in their comparative dosimetric study Wagner et al. 20 and
Thilmann et al. 21 pointed out that IMRT achieved better
target coverage with respect to 3D-CRT, scoring a V95%
improvement of 13.5 and 13.1%, respectively. This advantage
was much more significant when PTV was in proximity of
OARs (20). Lorentini et al. 22 reported that IMRT always
provides better target coverage than 3D-CRT, regardless the
clinical-dosimetric scenario. Moreover, the higher the num-
ber of PTV-OARs overlaps, the better the target coverage
provided by IMRT with respect to 3D-CRT.
In this study we used a daily fraction of 2.5 Gy for total dose
of 57.5 Gy with SIB-RA which is equivalent to 60 Gy/30
fractions. Similar daily fractionation was used in other studies
using SIB-IMRT.23-24 The progression free survival and overall
survival were 13 and 16 months respectively. Our results are
similar to Raymond et al. 25 who reported the results of
SIB-IMRT with TMZ in 35 patients with GBM. Doses of 60
Gy and 40 Gy were delivered in 20 fractions to the GTV and
the PTV (GTV plus a 15 mm margin), respectively. Median
OS was 14.4 months with median PFS of 7.7 months. Cho et
al. 23 reported the results of 40 patients (WHO grade III, 14
patients; grade IV, 26 patients) treated with SIB-IMRT, a dose
of 2.0 Gy was delivered to the planning target volume with a
SIB of 0.4 Gy to the gross tumor volume with a total dose of
60 Gy to the gross tumor volume and 50 Gy to the planning
target volume in 25 fractions during 5 weeks and 20 patients
received concurrent TMZ. At a median follow-up of 13.4
months (range, 3.7–55.9 months), median survival was 14.8
months. One and 2-year survival rates were 78% and 65%,
respectively, for patients with grade III tumors and 56% and
31%, respectively, for patients with grade IV tumors. Inferior
results were recorded in other studies; Sultanem et al.26
evaluated the efficacy of SIB-IMRT in 25 patients with GBM.
A dose of 60 Gy in 20 fractions of 3 Gy was given to the GTV,
whereas the PTV (GTV plus a 15 mm margin) received a
minimum of 40 Gy in 20 fractions of 2 Gy. Median survival
was 9.5 months, with disease progression observed in 21
patients (84%). Recent retrospective analysis of 54 patients
with GBM by Chen et al. 18 assessed whether IMRT improved
clinical outcomes compared with 3D-CRT. The median fol-
low-up was 13 months. Of the 54 patients, 50 (92.6%) com-
pleted the combined modality treatment (patients underwent
postoperative IMRT or 3D-CRT with concurrent and adju-
vant temozolomide). The 1-year overall survival rate (OS)
was 79.6%. The pattern of failure was predominantly local. A
comparative analysis revealed that no statistical difference
was observed between the IMRT group (n = 21) and the
3D-CRT group (n = 33) for 1-year OS (89.6% vs. 75.8%, P =
0.795), or 1-year progression-free survival (PFS) (61.0% vs.
45.5%, P = 0.867). The authors concluded that preliminary
results suggest that delivering standard radiation doses by
IMRT is unlikely to improve local control or overall survival
for GBM compared with 3D-CRT.
In all the previous studies the total dose, dose per fraction and
the PTV delineation are different from one study to another
in addition these studies were retrospective analysis and some
studies include both high grade gliomas and GBM.24, 25 In our
study, we used the RTOG recommendation for delineation of
both the PTV1 and PTV2, So, our PTV margins are generous
than previous studies. In the previous studies they considered
alpha/beta (α/β) ratio of 10 like our study and BED ranged
from 66.1 Gy 23, 72.5 Gy 25, 26 up to 126.9 Gy 24 and our BED
was 60 Gy to PTV2 which is the standard radiation dose for
GBM. All our patients received concurrent TMZ followed by
adjuvant TMZ in 6 patients. The local failure was 67% in our
patients and was the only pattern of failure with no distant
failures reported in our patients. Previous studies reported
equivalent local failure rates of more than 60%.24-26 Iuchi et al.
reported lower rate of local failure (24%) and he explained
this improved local control by the high BED of 126.9 given to
the GTV. On the other hand, he reported 32% leptomenin-
geal dissemination which was the commonest cause of death
(70%).
The limitation of our study includes a small number of pa-
tients, and there is no direct clinical comparison with patients
treated by the 3D-CRT technique. For dose calculations,
Acuros XB ‒ the most advanced dose calculation algorithm
available in Eclipse treatment planning system 27‒ was not
used in this study. Treatment plans were calculated using
AAA, which has its limitation in dose predicting accuracy in
the inhomogeneity media. Several studies 27-29 have recom-
mended to calculate treatment plans using Acuros XB, which
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is a more accurate dose calculation algorithm compared to
AAA.
Conclusion
SIB-RA is feasible and safe, with acceptable acute and late
toxicities, despite the large fractional doses that were deliv-
ered to the GTV. The shortening of overall treatment time
by using the SIB-RA technique could have better patient`s
convenience, as far as it is safe and provides a similar survival
outcome. From the dosimetric standpoint, SIB-RA is a supe-
rior technique with respect to 3D-CRT when there are over-
laps between OARs and PTV. In these situations, SIB-RA
allows for a better target coverage by maintaining at the
same time an equivalent OARs sparing.
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